InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,436.44
(
-0.50%
)
US TECH 100
18,201.20
(
-1.91%
)
Dow Jones
40,743.33
(
0.50%
)
Brent Oil
78.52
(
-0.80%
)
Bitcoin
66,138.16
(
-1.03%
)
Post# of 20775
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

montanus

Send PM Follow Ignore
Followers 13
Posts 1001
Boards Moderated 0
Alias Born 03/12/2009

montanus

Re: Ron Swanson post# 7095

Monday, 03/04/2013 1:47:16 PM

Monday, March 04, 2013 1:47:16 PM

Post# of 20775
"While bapineuzumab failed to show clinical benefit, the use of biomarkers clearly demonstrated the drug had engaged the target, reduced the amount of plaque and slowed neurodegeneration based upon the decrease in the amount of tau protein measured in the cerebral spinal fluid (CSF)."

http://finance.yahoo.com/news/novel-alzheimers-therapeutics-developer-says-130724320.html

DOWN WITH THE GRAVITY, UP WITH THE LEVITY

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up